PLX - Protalix BioTherapeutics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 557.71M
Enterprise Value 388.68M
Trailing P/E N/A
Forward P/E 11.56
PEG Ratio (5 yr expected) 1-0.16
Price/Sales (ttm)1.52
Price/Book (mrq)N/A
Enterprise Value/Revenue 32.34
Enterprise Value/EBITDA 6-4.91

Trading Information

Stock Price History

Beta (3Y Monthly) 3.86
52-Week Change 3-7.02%
S&P500 52-Week Change 36.00%
52 Week High 30.8300
52 Week Low 30.2700
50-Day Moving Average 30.4280
200-Day Moving Average 30.4350

Share Statistics

Avg Vol (3 month) 3251.64k
Avg Vol (10 day) 3197.9k
Shares Outstanding 5148.38M
Float 144.79M
% Held by Insiders 16.23%
% Held by Institutions 19.70%
Shares Short (Jun 28, 2019) 42.46M
Short Ratio (Jun 28, 2019) 46.56
Short % of Float (Jun 28, 2019) 41.70%
Short % of Shares Outstanding (Jun 28, 2019) 41.66%
Shares Short (prior month May 31, 2019) 42.68M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 210/1
Last Split Date 3Jan 3, 2007

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -69.75%
Operating Margin (ttm)-51.87%

Management Effectiveness

Return on Assets (ttm)-19.56%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)37.97M
Revenue Per Share (ttm)0.26
Quarterly Revenue Growth (yoy)55.50%
Gross Profit (ttm)24.94M
EBITDA -18.05M
Net Income Avi to Common (ttm)-26.48M
Diluted EPS (ttm)-0.1790
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)30.36M
Total Cash Per Share (mrq)0.2
Total Debt (mrq)59.72M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)1.75
Book Value Per Share (mrq)-0.40

Cash Flow Statement

Operating Cash Flow (ttm)-5.61M
Levered Free Cash Flow (ttm)-271.62k